• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Dogwood Therapeutics Inc.

    3/17/25 5:49:29 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DWTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Dogwood Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    92829J203

    (CUSIP Number)


    03/12/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92829J203


    1Names of Reporting Persons

    Orca Capital AG
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    GERMANY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    115,790.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    115,790.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    115,790.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.1 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 1,911,128 shares of Common Stock outstanding immediately after giving effect to the completion of the Issuer's registered offering as described in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on March 14, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Dogwood Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    44 Milton Ave, Alpharetta, GA 30009
    Item 2. 
    (a)Name of person filing:

    Orca Capital AG
    (b)Address or principal business office or, if none, residence:

    Sperlring 2 85276 Hettenshausen Deutschland
    (c)Citizenship:

    Germany
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    92829J203
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    115,790 shares of the Issuer's common stock, par value $0.001 per share
    (b)Percent of class:

    6.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    115,790

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    115,790

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Orca Capital AG
     
    Signature:/s/ Thomas Konig
    Name/Title:Thomas Konig/Director
    Date:03/17/2025
    Get the next $DWTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DWTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DWTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

    - Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction -   ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the third quarter ended September 30, 2025. "The Company continues to execu

    11/6/25 8:45:00 AM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    -A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026- -SP16 has demonstrated both anti-inflammatory and neural repair activity that has the potential to treat CIPN, synergistically complementing Halneuron®, the Company's late stage NaV1.7 inhibitor, which has demonstrated significant pain reduction in previous Phase 2 studies- -Webcast today, September 29, 2025, at 8:30 a.m. Eastern Time- ATLANTA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) ("Dogwood" or the "Company"), a

    9/29/25 7:15:00 AM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

    ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) --  Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel. Greg Duncan, Chief Executive Officer will participate in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright on September 5, 2025. Time: Available on-demand beginning at 7:00am ETWebcast Link:https://journey.ct.events/view/20673857-761f-4856-b863-2a5fbe671f6

    9/3/25 9:15:00 AM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Walsh Angela

    4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

    12/5/25 4:05:12 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP OF OPERATIONS Grosswald Ralph

    4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

    12/5/25 4:05:10 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Duncan Gregory Scott

    4 - Dogwood Therapeutics, Inc. (0001818844) (Issuer)

    12/5/25 4:05:15 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DWTX
    SEC Filings

    View All

    Dogwood Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

    11/28/25 2:15:10 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Dogwood Therapeutics Inc.

    424B5 - Dogwood Therapeutics, Inc. (0001818844) (Filer)

    11/28/25 2:00:50 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dogwood Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Dogwood Therapeutics, Inc. (0001818844) (Filer)

    11/21/25 1:01:26 PM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DWTX
    Financials

    Live finance-specific insights

    View All

    Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

    - Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction -   ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the third quarter ended September 30, 2025. "The Company continues to execu

    11/6/25 8:45:00 AM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

    - Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain ("CINP") Phase 2b study interim data readout remains on track for Q4 2025 - - Low discontinuation rate (5.8%) due to adverse events in the first 38 patients completing the trial suggests Halneuron® and placebo treatment have been generally well tolerated - - Cash on hand of $13.4 million provides operational runway through Q1 2026 - ATLANTA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced

    8/13/25 9:00:00 AM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

    ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) (the "Company"), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, announced today that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (NASDAQ:DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The prop

    8/6/25 9:15:00 AM ET
    $DWTX
    Biotechnology: Pharmaceutical Preparations
    Health Care